FOLH1 and neoplasm: The success of prostate-specific membrane antigen (PSMA), labeled with Lutetium-177 (177Lu), in the treatment of patients with castration-resistant prostate cancer74 has paved the way for investigating radioligand therapy in the treatment of other tumor types.